Congratulations! The IPO of WOLW biological pharmaceutical enterprise, one of many enterprises which are invested by our fund, has passed the examination and verification of Growth Enterprise Market (GEM) Issuance and examination commission of China Securities Regulatory Commission (CSRC) at 48th GEM Issuance and examination commission meeting on June 12, 2012.
WOLW plans to issue 30 million shares on Shenzhen Stock Exchange this time, which are accounting for 25% of company's total shares after the IPO. WOLW is an enterprise of which main business is the R&D, production and sale of allergens products. The approved marketing products includes “dermatophagoides farina drops ” (trade name: Chang Di) and “dermatophagoides farina diagnostic kit” (trade name: Chang Dian).